Published on: November 27, 2021

PRODUCTION LINKED INCENTIVE (PLI) SCHEME FOR THE PHARMACEUTICAL SECTOR

PRODUCTION LINKED INCENTIVE (PLI) SCHEME FOR THE PHARMACEUTICAL SECTOR

buy genuine Misoprostol in the u.s. NEWS

viviparously The PLI Scheme for Pharmaceuticals is based on the strategy of “Atmanirbhar Bharat- Strategies for enhancing India’s manufacturing capabilities and enhancing exports in ten sectors”, which had been approved by the Union Cabinet

ABOUT

  • Objective
    • Enhance India’s manufacturing capabilities by increasing investment and production in the sector
    • Contributing to product diversification to high value goods in the pharmaceutical sector
    • Create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.
  • Provide financial incentives on the incremental sales (over Base Year) of pharmaceutical goods and in-vitro diagnostic medical devices to selected applicants based on pre-defined selection criteria
  • Incentives will be paid for a maximum period of 6 years for each participant depending upon the threshold investments and sales criteria to be achieved by the applicant.
  • SIDBI – Project Management Agency for the Scheme.
  • The scheme covers three different product categories for which applicants have applied under the scheme. These products are expected to give an impetus to innovation, R&D and widening of product profile of India Pharmaceutical industry.
    • Category 1: Biopharmaceuticals; Complex generic drugs; Patented drugs or drugs nearing patent expiry; Cell based or gene therapy drugs; Orphan drugs; Special empty capsules like HPMC, Pullulan, enteric etc.; Complex excipients; Phyto-pharmaceuticals.
    • Category 2: Active Pharmaceutical Ingredients / Key Starting materials / Drug Intermediates (except the Active Pharmaceutical Ingredients / Key Starting materials / Drug Intermediates covered under the earlier PLI scheme for APIs/KSMs and DIs being implemented by the Department)
    • Category 3 (Drugs not covered under Category 1 and Category 2): Repurposed drugs; Auto immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs; In vitro diagnostic devices; Other drugs not manufactured in India.
  • The selection of applicants in each of the three categories has been approved by the Hon’ble Minister for Chemicals and Fertilizers.
  • A Technical Committee comprising of experts is assisting the Department with respect to the technical aspects of the scheme.
  • SIDBI has put in place a digital mechanism for business processes being followed under the scheme.
  • A robust monitoring framework will also be put in place to track the progress of the scheme.